Therapeutic potential for acute myeloid leukemia and dual function of RBM5 are revealed by HOXA9 tracking.

Published Date: 17 Jan 2024

The majority of cases of acute myeloid leukemia (AML) are associated with overexpression of the protein HOXA9, which is linked to poor patient outcomes. However, HOXA9 is a difficult protein to target therapeutically, so researchers at St. Jude Children's.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot